On The Horizon

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

By Malecare|2016-04-28T16:08:19-04:00April 28th, 2016|Advanced Prostate Cancer, Clinical Trials & Research, Drugs & Treatments, On The Horizon, survival, Survival, Uncategorized|2 Comments

More From ASCO GU 2016 – ExoDx™ Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test from a Simple Urine Sample

The constant hope and conversation of late has surrounded what is referred to as a liquid biopsy. The hope and goal is to no longer need to have an invasive needle biopsy to diagnose and stage prostate cancer. Biopsies are not accurate because there are too many false negatives, they only evaluate the actual tissue [...]

By Malecare|2023-07-08T15:57:45-04:00March 10th, 2016|Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, Disparities, genetics, Genetics and Geonomics, On The Horizon, prognostic tools, Screening, Uncategorized|0 Comments

CTC Heterogeneity Predicts Prostate Cancer Drug Sensitivity

This afternoon I am off to the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco. There has already been some information leaking to the media about some of the presentations that will be going on at the conference. One such “leak” is about findings from Memorial Sloan Kettering Cancer Center [...]

By Malecare|2017-10-19T10:46:41-04:00January 6th, 2016|Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, CTCs, On The Horizon, prognostic tools, Research, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments

On The Horizon – Tests That Can Inform Us If A Drug Will Work Before We Take The Drug

We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]

By Malecare|2017-10-19T10:46:49-04:00November 12th, 2015|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, CTCs, Drugs & Treatments, Enzalutamide (MDV-3100), On The Horizon, prognostic tools, Research, taxanes, Uncategorized, Xtandi, Zytiga|0 Comments

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]

By Malecare|2020-02-04T11:45:03-05:00April 9th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, survival, Tasquinimod (TASQ), Uncategorized|1 Comment

Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials

There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]

By Malecare|2017-10-19T10:47:29-04:00March 27th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, CTCs, General Information, On The Horizon, Uncategorized, Understanding APC, Zytiga|0 Comments

Prostvac In Combination With Yervoy Yields A Survival Advantage

There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]

By Malecare|2017-10-19T10:47:30-04:00February 24th, 2015|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, immunotherapy, ipilimumab, NCI, On The Horizon, Uncategorized, Yervoy|7 Comments

On the Horizon – Circulating Tumor Cells in the Clinic – We are Waiting

It isn’t here yet, but it very much is here! What am I talking about? Circulating tumor cells (CTCs) are going to become a clear winner for us as the concept of using them finds its way into commercialization. Metastatic castration resistant prostate cancer (mCRPC) is difficult to evaluate using our less than stellar conventional [...]

By Malecare|2015-01-16T16:42:57-05:00January 16th, 2015|Advanced Prostate Cancer, CTCs, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC|0 Comments

Blocking Bone Metastases in Prostate Cancer by Using Approved HIV Drugs

Normally I don't write about pre-clinical things unless they are particularly interesting. You guessed it; I found a preclinical item that is interesting. According to a recent published study by Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University the receptor CCR5, which is targeted by already approved [...]

By Malecare|2020-02-04T11:33:15-05:00December 16th, 2014|Advanced Prostate Cancer, Bone Metastases, CCR5, On The Horizon, Research, Uncategorized|0 Comments

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

By Malecare|2017-10-19T10:47:58-04:00September 30th, 2014|2nd line hormone therapy, abiraterone acetate, adjuvant therapy, ADT, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Androgan Receptor Inhibitor, Bio Chemical Recurrence, biomarkers, bisphosphonates, Bone Health, Bone Metastases, Bone Mineral Density, CAB, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Cross Resistance, Cryotherapy, CTCs, denosumab - Xgeva, Diet, Diet and Supplements, Drugs & Treatments, Early Access Program (EAP), Early/Expanded Access Programs, End-Of-Life, enzalutamide, estrogen patches, FDA, Financial, Firmagon (degarelix), General Information, genetics, HIFU, Hormone Therapy, Hot Flashes, How We Live, immunotherapy, Incontinence, inflammation, ipilimumab, ketoconazole, Medicare/Medicaid, mental health, Metastases, MRIs, NCI, neuroendocrine prostate cancer, neutropenia, Nilandron, oligometastic, On The Horizon, Our Caretakers, Pain, perineural invasion, peripheral neuropathy, Personal Experiences, prognostic tools, Prostate Ponderings, Prostvac, Provenge, PSA, PSADT, Quality of Life, radiation proctitis, radiopharmaceuticals, Radiotherapy, Research, Revlimid (lenalidomide), salvage therapy, statins, supplements, survival, survivorship, TAK700, teleconferences, Uncategorized, Understanding APC, vaccines, Vitamine D3, weight gain, Xgeva, XL184, Xofigo, Xtandi, Zometa, Zytiga|1 Comment